Targets › SELP
1 program from 1 company in 4 trials: 2 Phase 3, 1 Phase 4, 1 Phase 2; Hematology, Oncology; next expected readout Jul 2029.
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. (UniProt, P16109)
Open in Phaseline: the race on SELP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Crizanlizumab (SEG101) P-selectin blocker | SELP | Phase 4 | Sickle Cell Disease; Sickle Cell Disease (SCD); Advanced Glioblastoma | Jul 2029 |
Sickle Cell Disease (2) Sickle Cell Disease (SCD) (1) Advanced Glioblastoma (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.